Skip to main content

CORRECTION article

Front. Pharmacol., 26 October 2023
Sec. Inflammation Pharmacology

Corrigendum: Naringenin protects against acute pancreatitis-associated intestinal injury by inhibiting NLRP3 inflammasome activation via AhR signaling

Xu YanXu YanTianjiao LinTianjiao LinQingyun ZhuQingyun ZhuYushi ZhangYushi ZhangZhimin SongZhimin SongXinting Pan
Xinting Pan*
  • The Affiliated Hospital of Qingdao University, Qingdao, China

A Corrigendum on
Naringenin protects against acute pancreatitis-associated intestinal injury by inhibiting NLRP3 inflammasome activation via AhR signaling

by Yan X, Lin T, Zhu Q, Zhang Y, Song Z and Pan X (2023). Front. Pharmacol. 14:1090261. doi: 10.3389/fphar.2023.1090261

In the published article, there was an error in Figure 3 as published. The image of the DEX group in Figure 3A was inadvertently misused during the final assembly of Figure 3. The corrected Figure 3 and its caption are provided herein.

FIGURE 3
www.frontiersin.org

FIGURE 3. Naringenin inhibits activation of the NLRP3 inflammasome. (A) Immunohistochemical staining was performed on ileum sections to detect NLRP3. (B) Relative expression levels of NLRP3 mRNA in the intestine, as analyzed by real-time PCR. (C) Western blot analysis of NLRP3 expression in the intestine of each group and corresponding grayscale statistics. ***p < .0001 vs. NS; ###p < .0001 vs. SAP, ΔΔP.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: severe acute pancreatitis, intestinal injury, naringenin, AhR, NLRP3 inflammasome

Citation: Yan X, Lin T, Zhu Q, Zhang Y, Song Z and Pan X (2023) Corrigendum: Naringenin protects against acute pancreatitis-associated intestinal injury by inhibiting NLRP3 inflammasome activation via AhR signaling. Front. Pharmacol. 14:1295494. doi: 10.3389/fphar.2023.1295494

Received: 16 September 2023; Accepted: 18 October 2023;
Published: 26 October 2023.

Edited and reviewed by:

Olumayokun Olajide, University of Huddersfield, United Kingdom

Copyright © 2023 Yan, Lin, Zhu, Zhang, Song and Pan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xinting Pan, MDUzNnB4dEAxNjMuY29t

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.